Revealing the epigenetic effect of temozolomide on glioblastoma cell lines in therapeutic conditions.
Temozolomide (TMZ) is a drug of choice in glioblastoma treatment. Its therapeutic applications expand also beyond high grade gliomas. However, a significant number of recurrences and resistance to the drug is observed. The key factor in each chemotherapy is to achieve the therapeutic doses of a drug...
Main Authors: | Agnieszka Belter, Jakub Barciszewski, Anna-Maria Barciszewska |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2020-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0229534 |
Similar Items
-
A New Epigenetic Mechanism of Temozolomide Action in Glioma Cells.
by: Anna-Maria Barciszewska, et al.
Published: (2015-01-01) -
Reveal the involvement of CEBPD in stemness and Temozolomide resistance of glioblastoma
by: Wen-ChiLin, et al.
Published: (2018) -
Quinacrine enhances temozolomide cytotoxicity in temozolomide-sensitive and -resistant glioblastoma cells
by: Pingde Zhang, et al.
Published: (2018-01-01) -
Correlation between Methylation Status of MGMT and Therapeutic Effect of Temozolomide in Glioblastoma
by: KAN,CHIA-HUA, et al.
Published: (2017) -
Synergistic Effects of Resveratrol and Temozolomide Against Glioblastoma Cells: Underlying Mechanism and Therapeutic Implications
by: Liu Y, et al.
Published: (2020-09-01)